Business
For its autocratic African ally, Taiwan bites its tongue and opens its wallet
By Marcus Chen
China’s Hengrui posts 89% rise in third-quarter net profit, beating estimates
Marcus Chen
Marcus Chen
Managing Editor · St. Paul, MN
Marcus manages the day-to-day editorial workflow across all brands, coordinating coverage assignments and ensuring editorial standards are met. He previously served as city editor at the Pioneer Press and holds a degree in Political Science from Carleton College.
More from Marcus →Managing Editor · Tuesday, October 27, 2026 at 11:30 AM · 1 min read
Jiangsu Hengrui Pharmaceuticals, one of China’s largest drug makers, reported a 20.55 per cent rise in third-quarter revenue to 8.95 billion yuan (US$1.34 billion), beating analyst estimates of 8.55 billion yuan amid stronger innovative drug sales. Net profit reached 2.46 billion yuan for the three months ended September 30, jumping 88.92 per cent year on year and exceeding the Bloomberg analyst consensus estimate of 2.38 billion yuan. Improving innovative drug sales and out-licensing revenue...
Up nextFor its autocratic African ally, Taiwan bites its tongue and opens its walletBusiness · 1 min read
